What's Happening?
The NFL and the NFL Players Association (NFLPA) have agreed to conduct a joint review into the circumstances surrounding Philadelphia Eagles quarterback Jalen Hurts' recent blood clot diagnosis. This decision follows a statement from Jeff Miller, the NFL's
executive vice president of communications, public affairs, and health policy, confirming that independent medical experts, mutually agreed upon by both organizations, will examine the matter. Hurts was diagnosed with deep vein thrombosis and bilateral pulmonary emboli after a blood clot, initially superficial in his leg, moved to his lungs. He had reported being cleated during a Week 4 game against the Los Angeles Rams and subsequently played in a Week 5 game in London after an ultrasound revealed the superficial clot but cleared him to play. A follow-up ultrasound after returning home showed the clot had moved. Hurts was placed on injured reserve in October and is expected to miss the remainder of the 2026 season. He is currently taking blood thinners and is reported to be clinically stable with a good prognosis for full recovery.
Why It's Important?
This joint review is significant as it could lead to new league-wide guidance regarding clotting disorders among players. The NFL has tracked such disorders for at least a decade through a subcommittee of its General Medical Committee, sharing this information with the NFLPA. The findings from this independent medical review will inform both the NFL and NFLPA on potential next steps, which could include adjustments to medical protocols, player safety guidelines, or even the Collective Bargaining Agreement. The case highlights the complex medical challenges faced by professional athletes and the need for robust systems to monitor and respond to serious health conditions. For players, it underscores the importance of thorough medical evaluations and the potential risks associated with playing through injuries. For the league, it's an opportunity to reinforce its commitment to player health and safety, potentially setting new standards for medical clearance and injury management.
What's Next?
The joint review by independent medical experts is underway, with their conclusions and recommendations to be shared with both the NFL and NFLPA. Following this review, the league and the players' association will consider appropriate next steps, including whether additional league-wide guidance is necessary. This could involve revising existing protocols for diagnosing and managing blood clots, enhancing pre-game medical screenings, or implementing new educational initiatives for players and medical staff. Senator Lisa Blunt Rochester, who had previously written to NFL Commissioner Roger Goodell seeking answers about Hurts' diagnosis and the league's blood clot protocol, has expressed appreciation for the NFL's transparency and encouraged leadership to use this moment to increase awareness of deep vein thrombosis (DVT) and pulmonary embolism (PE) to better protect players and support public health. Hurts is expected to resume contact football activities once he is off blood thinners.
Beyond the Headlines
The incident with Jalen Hurts brings to light the broader implications of player health in high-stakes professional sports. Beyond the immediate medical review, this situation could spark discussions about the pressures on athletes to play through injuries, the adequacy of current medical clearance procedures, and the long-term health consequences of professional football. It also raises questions about the balance between competitive demands and player well-being, particularly when dealing with less visible but potentially life-threatening conditions like blood clots. The involvement of independent medical experts underscores a commitment to objectivity and thoroughness, which could set a precedent for how similar complex medical cases are handled in the future. This event may also contribute to increased public awareness of DVT and PE, not just within the athletic community but for the general population, emphasizing the importance of early detection and treatment.
